SG11201808774RA - Treatment of renal cell carcinoma with lenvatinib and everolimus - Google Patents
Treatment of renal cell carcinoma with lenvatinib and everolimusInfo
- Publication number
- SG11201808774RA SG11201808774RA SG11201808774RA SG11201808774RA SG11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA SG 11201808774R A SG11201808774R A SG 11201808774RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lenvatinib
- everolimus
- april
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011111111011111001101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number ..... .....1 (43) International Publication Date WO 2017/179739 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/47 (2006.01) A61K 31/436 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/48 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/JP2017/015461 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 17 April 2017 (17.04.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 2016-081787 15 April 2016 (15.04.2016) JP kind of regional protection available): ARIPO (BW, GH, 62/322916 15 April 2016 (15.04.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: EISAI R&D MANAGEMENT CO., LTD. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [JP/JP]; 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 1128088 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (JP). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — (72) Inventor: KREMER Alton; c/o Eisai Inc., 155 Tice Blvd, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Woodcliff Lake, NJ, 07677 (US). Agents: HASEGAWA Yoshiki et al.; SOEI PATENT Published: (74) = AND LAW FIRM, Marunouchi MY PLAZA (Meiji Yas- — with international search report (Art. 21(3)) uda Life Bldg.) 9th fl., 1-1, Marunouchi 2-chome, Chiyo - da-ku, Tokyo, 1000005 (JP). = = = = = = = = = = = = = 1-1 C:7 M IN C:7 IN 11 IN 11 © (54) Title: TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS ei O (57) : Methods and compositions for treating a renal cell carcinoma with the combination of lenvatinib or a pharmaceutic - ally acceptable salt thereof and everolimus are provided. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322916P | 2016-04-15 | 2016-04-15 | |
JP2016081787 | 2016-04-15 | ||
PCT/JP2017/015461 WO2017179739A1 (en) | 2016-04-15 | 2017-04-17 | Treatment of renal cell carcinoma with lenvatinib and everolimus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808774RA true SG11201808774RA (en) | 2018-11-29 |
Family
ID=60041779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808774RA SG11201808774RA (en) | 2016-04-15 | 2017-04-17 | Treatment of renal cell carcinoma with lenvatinib and everolimus |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3442532A4 (en) |
KR (1) | KR20180129795A (en) |
CN (1) | CN108883106A (en) |
AU (1) | AU2017249459A1 (en) |
CA (1) | CA3019682A1 (en) |
SG (1) | SG11201808774RA (en) |
WO (1) | WO2017179739A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109793736A (en) * | 2019-01-31 | 2019-05-24 | 徐州医科大学 | A kind of pleasure cuts down the application for Buddhist nun in preparation natural killer cells agonist |
CN116406288A (en) * | 2020-06-17 | 2023-07-07 | 默沙东有限责任公司 | Methods for treating cancer or von-hippel-lindau disease using a combination of a PD-1 antagonist, a HIF-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1698623T1 (en) * | 2003-12-25 | 2015-07-31 | Eisai R&D Management Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
-
2017
- 2017-04-17 KR KR1020187028053A patent/KR20180129795A/en not_active Application Discontinuation
- 2017-04-17 CN CN201780020786.5A patent/CN108883106A/en active Pending
- 2017-04-17 SG SG11201808774RA patent/SG11201808774RA/en unknown
- 2017-04-17 EP EP17782552.8A patent/EP3442532A4/en active Pending
- 2017-04-17 WO PCT/JP2017/015461 patent/WO2017179739A1/en active Application Filing
- 2017-04-17 CA CA3019682A patent/CA3019682A1/en active Pending
- 2017-04-17 AU AU2017249459A patent/AU2017249459A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN108883106A (en) | 2018-11-23 |
EP3442532A1 (en) | 2019-02-20 |
WO2017179739A1 (en) | 2017-10-19 |
EP3442532A4 (en) | 2019-12-11 |
AU2017249459A1 (en) | 2018-10-25 |
CA3019682A1 (en) | 2017-10-19 |
KR20180129795A (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201901501UA (en) | Compositions and methods for enhancing cancer radiotherapy | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810192TA (en) | Antibacterial compositions | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201900043TA (en) | Antibody formulations | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |